First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228
Clinical trial NCT05737628 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05737628
- Sponsor
- Byondis B.V.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-04
- Primary completion
- 2026-02-01
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.